Ipilimumab
An inhibitor of CTL A-4 lymphocyte domain used to treat melanoma (PMID 23714523). Reviews on management of AE at PMID 23772560, 24278787. Incidence of ILD higher if ipilumab and nivolumab are given concomitantly (PMID 25891304)
Back
The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
I - Interstitial/parenchymal lung disease
I.a
Pneumonitis (interstitial lung disease/ILD)
I.b
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.e
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.n
ILD with a granulomatous component
I.w
Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
XLI - Pulmonary edema - Acute lung injury - ARDS
XLIII - Airway involvement
XLV - Pleural and/or pericardial involvement
XLVII - Mediastinal involvement
XLVIII - Neuromuscular / CNS involvement - Disordered breathing (during sleep)
XLIX - Systemic/Distant conditions, syndromes and reactions
XLIX.a
DRES syndrome - DRESS-like reaction
XLIX.e
Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
XLIX.i
Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
XLIX.l
Myopathy-Myositis-Polymyositis (see also under Xba)
XLIX.m
Sarcoid-like granulomatosis (endo-/extrathoracic)
XLIX.n
Systemic granulomatosis other than Xk
XLIX.q
Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
XLIX.ao
Immune-related adverse effect/toxicity